Organization
Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
8 abstracts
Abstract
FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study.Org: Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli–IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy, Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, Pisa, Italy, Department of Oncology and Palliative Care, Cardinale G Panico, Tricase City Hospital, Tricase, Italy,
Abstract
Impact of hormone receptor status and tumor subtypes on clinical behavior and outcomes of breast cancer in young BRCA carriers.Org: Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genoa, Genoa, Italy, Academic Trials Promoting Team, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium, U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy, Department of Medical Oncology, Universite Paris Cité, Institut Curie, Paris, France, Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea,
Abstract
Dose-dense adjuvant chemotherapy in patients with HER2-low early breast cancer: An exploratory analysis of the GIM2 trial.Org: Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Clinical Oncology Department, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Department of Clinical Medicine and Surgery, Università Federico II, Napoli, Italy, Medical Oncology Department, ASL FR, Frosinone, Italy, Precision Medicine Unit in Senology Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy,
Abstract
Early prediction of endocrine responsiveness in ER+/HER2 negative MBC: Pilot study with 18F-fluoroestradiol (18F-FES) CT/PET.Org: EO Ospedali Galliera, University Hospital Munich, International Breast Cancer Center (IBCC), Vall d'Hebron Institute of Oncology, Maggiore della Carità University Hospital,
Abstract
Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO.Org: Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana and Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Charité Universitätsmedizin Berlin, Berlin, Germany, Oncology Unit 1, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy, Department of Medical Oncology, University Campus Biomedico, Roma, Italy, Division of Clinical Pharmacology and Oncology, Department of Health Sciences, School of Psychology, University of Florence, Florence, Italy, University of Pisa, Pisa, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS Padua, Padua, Italy, U.O.C. Oncologia Medica, Presidio Ospedaliero Livorno, Livorno, Italy, Hämatologisch Onkologische Praxis Eppendorf (HOPE) and Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, Department of Oncology, Istituto Scientifico San Raffaele IRCSS, Milan, Italy, CdC Poliambulanza, Brescia, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS, Padua, Italy, IRCSS-CRO Aviano, Department of Clinical Oncology, Aviano, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Martin Luther University, Halle, Germany, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, Medical Oncology 1, Department of Oncology, Veneto Institute of Oncology IOV–IRCCS, Padova, Italy, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy,
Abstract
2007 UPDATE OF THE FRENCH NATIONAL GUIDELINES FOR THE USE IN DAILY PRACTICE OF TNF-BLOCKERS IN PEOPLE SUFFERING FROM RHEUMATOID ARTHRITISOrg: University of Paris 6, Pitié Salpêtrière Hospital, Immuno Rheumatology, CHU Montpellier, CHU Marseille,
Abstract
Association between tnf -308a and systemic lupus erythematosus in relation to hla-dr3 and six microsatellite markers on the short arm of chromosome viOrg: Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Immunohaematology and Blood Transfusion, Rheumatology, Society of Patients with Rheumatism, Cracow, Poland, General Internal Medicine, Leiden University Medical Centre, Leiden, Netherlands,
Abstract
Biomechanical therapy for osteoarthritis of the knee: a randomised controlled trial (BIOTOK)Org: University of Bern, Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Boston University Chobanian & Avedisian School of Medicine, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester National Rheumatoid Arthritis Society (NRAS), Maidenhead Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK, Applied Health Research Centre (AHRC),